Want to see OTLC full AI Analyst Report?
OTLC Stock Chart & Stats
$0.08
>-$0.01(-12.62%)
At close: 4:00 PM EST
$0.08
>-$0.01(-12.62%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume643.67K
Average Volume (3M)410.07K
Market Cap
$17.87M
Enterprise Value$31.21
Total Cash (Recent Filing)$63.61B
Total Debt (Recent Filing)$16.79T
Price to Earnings (P/E)<0.1
Beta-0.07
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.58
Shares Outstanding443,615,720
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported debt-to-equity near 0.06 indicates limited reliance on third-party debt financing, preserving near-term financial flexibility and lowering insolvency risk. This structural conservatism can cushion operations while early-stage programs progress and reduces mandatory interest burdens over the next several quarters.
Strategic IP Stake From LunaiThe non-cash acquisition of preferred equity plus a perpetual license materially augments Oncotelic's IP access and balance-sheet optionality. This structural asset provides R&D leverage, potential future monetization or partnerships, and reduces the need to develop certain IP internally, supporting sustainable pipeline expansion.
Platform & Clinical ProgressAdvancing multiple clinical programs and formalizing Sapu Bio/Nano plus external CRO partnerships indicates a scalable development platform. Persistent clinical progress and an operational GMP facility create durable R&D momentum, diversify program risk, and improve long-term probability of value-generating catalysts.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow demonstrates structural cash burn and an inability to self-fund development. Over 2-6 months this forces reliance on financing, increases execution risk for trials, and limits capacity to scale operations without dilutive or costly capital infusions.
Minimal Revenue And Operating LossesNear-zero revenue and recurring operating losses indicate a lack of commercial traction and absent margin support. This structural weakness makes profitability distant, constrains internal reinvestment, and heightens dependence on external capital or asset monetization to sustain R&D and operations.
Reliance On Dilutive Convertible FinancingFrequent use of short-term convertible notes with discounts, interest and upfront commitment shares signals dependence on dilutive private financing. Such instruments create refinancing and shareholder dilution risk and can pressure governance and capital structure if clinical timelines or uplisting targets slip.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $17.87M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 33 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Currently, no data Available
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 443,615,720 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.